Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

ICPs recent rebound has sparked breakout talk, with traders watching whether momentum can clear nearby resistance after repeated rejections. The community is split between optimism about the move and ICPs decentralized-compute and AI-infrastructure thesis, and frustration over weak follow-through, lagging performance, and adoption still needing to prove itself.

Traders are speculating that Johnson & Johnson could acquire Sellas Life Sciences, citing J&Js oncology ambitions and Sellass cancer-drug pipeline ahead of the REGAL trial readout. The rumored deal is unconfirmed, and the community also names other potential buyers.

GameStops roughly 10% stake in eBay and its takeover effort dominate discussion, with traders debating whether the bid could lead to a deal or partnershipor be abandoned. Views are split between takeover-driven optimism and skepticism about the transactions feasibility, alongside some attention to eBays earnings and standalone business.

Avis Budgets earnings disappointment and heavy debt are fueling bearish talk about further declines and financial risk, while traders also debate whether the stock could repeat its earlier short squeeze. The conversation reflects sharp volatility and a split between fundamental concerns and squeeze speculation.

AbbVie is drawing attention for a breakout to fresh highs, with traders citing healthcare-sector strength and bullish momentum; discussion also points to positive pipeline updates and analyst upgrades, while some question whether the rally can hold.

PEPE is drawing attention for a modest bounce after an extended stretch of weakness, but traders describe price action as largely sideways around the 4 level. Some are watching for a bullish breakout, while others warn the bounce could fade and focus on resistance near 5.

Elevated refining margins amid tight diesel and other refined-fuel supplies are driving attention to MPC and its peer refiners, with traders highlighting the sectors repeated highs. The rally has also prompted profit-taking and debate over whether margins can stay elevated, particularly amid valuation concerns and possible policy changes that could affect fuel exports.

TG Therapeutics MSToronto presentationsparticularly late-breaking Phase 1 azer-cel findings in progressive MS, alongside BRIUMVI trial resultsare driving attention. Traders see the presentation slot as encouraging, but its significance for efficacy remains uncertain; discussion also includes anticipation of BRIUMVI subcutaneous data and speculative buyout and short-squeeze theories.

SELLASs larger-than-usual ASH conference presence is fueling speculation about upcoming REGAL Phase 3 results and a possible buyout or partnership, with traders also watching for SLS009 data. Bulls interpret the booth and the prolonged quiet period as signs of positive developments or deal talks, while skeptics say neither the booth nor delayed reporting confirms trial success or an acquisition.

ENAs rally is drawing attention alongside traders bullish discussion of Ethenas USDe growth and a reported Standard Chartered outlook; some also point to the approved fee-switch buyback framework, which would depend on USDe reaching its supply trigger before purchases begin. Bulls see adoption and potential buybacks supporting ENAs value, while others remain wary of token supply, unlocks, and pullbacks.